loader2
Login Open ICICI 3-in-1 Account
IPOLogoImag

AKUMS DRUGS AND PHARMACEUTICALS IPO

IPO Details

-
-
22 Shares
₹ 14,938
₹ 646 – 679
₹ Up to 1856.74 Cr

Issue timeline

  • -
  • 02-Aug-2024
  • 05-Aug-2024
  • 05-Aug-2024
  • 06-Aug-2024

Subscription Status

Shareholder -
Qualified Institutional Buyers -
Non-Institutional Investor -
Retail Individual Investor -
Employee -
Total -

About Company

- A pharmaceutical contract development and manufacturing organization (“CDMO”) offering a comprehensive range of pharmaceutical products and services in India and overseas
- During the FY24, they had a market share of 30.2% of the Indian domestic CDMO market by value, which increased from 26.7% during the FY21
- Since their inception, they have manufactured 4,146 commercialised formulations across over 60 dosage forms

Strengths & Risks

Strengths (3)

Largest CDMO serving the Indian pharmaceutical industry

The largest India-focused CDMO in terms of revenue, production capacity and clients served during the FY23 (among CDMOs assessed by F&S). Along with its subsidiaries, as of March 31, 2024, they operate 12 manufacturing units with a cumulative formulations manufacturing capacity aggregating to 49.23 billion units annually, to produce a wide range of dosage forms (Source: F&S Report)

Risks (2)

Any slowdown or shutdown in manufacturing and R & D operations could have an adverse effect on business

Business is dependent upon their ability to operate manufacturing units and R&D centers without disruption. Factors beyond their control, including disruption in electrical power or water resources, political instability, industrial accidents or machinery breakdowns, severe weather conditions, natural disasters, and outbreak of infectious diseases, could result in a slowdown or shutdown of their operations and adversely affect business. (Source: Company RHP)

Financials

Industry Overview

- Resilient and sustainable long-term growth has been evident in the pharma segment : The pharmaceutical market is pivotal in advancing global healthcare, encompassing critical aspects such as research, development, manufacturing, and distribution of pharmaceutical products, including drugs, vaccines, and biotechnology-based therapies. Valued at USD 1,634.8 billion in 2023, the market is projected to reach USD 2,119.0 billion by 2027, with a CAGR of 6.7% from 2023 to 2027


- India is emerging as the preferred destination for pharma outsourcing: In the realm of pharmaceuticals, a notable shift has emerged where both Indian and International pharmaceutical firms are showing a growing inclination toward collaborating with Indian CDMOs. This preference is attributed to several compelling business factors: Cost Efficiency, Expert talent pool, Ease of doing business, Government policies supporting local pharma manufacturing,Government’s FDI policy for the pharma sector,Regulatory-compliant infrastructure,Scalability, customization, and flexibility,Access to technology, Diversity in formulation capability

Akums Drugs IPO FAQs

What is the minimum lot size and investment required for Akums?

The lot size is 22 shares and minimum investment required is Rs.14,938 for Akums

Akums Drugs IPO is mainboard IPO of issue size up to Rs.1856.74 Crores

Akums Drugs IPO issue dates are from 30th July – 01st Aug, 2024.

The allotment date is 2nd Aug, 2024 and listing date is 6th Aug, 2024 for Akums Drugs IPO.

Head to IPO section on ICICI Direct website and select Akums Drugs IPO. Enter and submit bid details and then click on proceed to apply once details are verified. It’s that simple!!

View More

*The financials mentioned above are sourced from DRHP/ RHP documents.